2017年　業績集

  1. Iida S, Nagai H, Kinoshita G, Miyoshi M, Robbins M, Pandya D, Bleickardt E, Chou T. Elotuzumab with lenalidomide and dexamethasone for Japanese patients with relapsed/refractory multiple myeloma: phase 1 study.
    Int J Hematol 2017;105(3): 326-334.
  2. Shinkai N, Kusumoto S, Murakami S, Ogawa S, Ri M, Matsui T, Tamori A, Toyoda H, Ishida T, Iida S, Tanaka Y.
    Novel monitoring of hepatitis B reactivation based on ultra-high sensitive hepatitis B surface antigen assay.
    Liver Int. 2017; 37(8): 1138-1147.
  3. Suzuki K, Ri M, Chou T, Sugiura I, Takazako N, Sunami K, Ishida T, Izumi T, Ozaki S, Shumiya Y, Ota K, Iida S.
    Carfilzomib, lenalidomide, and dexamethasone in patients with heavily-treated multiple myeloma: A phase 1 study in Japan.
    Cancer Sci 2017; 108 (3): 461-468.
  4. Suzuki K, Sunami K, Ohashi K, Iida S, Mori T, Handa H, Matsue K, Miyoshi M, Bleickardt E, Matsumoto M, Taniwaki M.
    Randomized phase 3 study of elotuzumab for relapsed or refractory multiple myeloma: ELOQUENT-2 Japanese patient subanalysis.
    Blood Cancer J. 2017; 7: e540.
  5. Tatekawa S, Chinen Y, Ri M, Narita T, Shimura Y, Matsumura-Kimoto Y, Tsukamoto T, Kobayashi T, Kawata E, Uoshima N, Taki T, Taniwaki M, Handa H, Iida S, Kuroda J.
    Epigenetic repression of miR-375 is the dominant mechanism for constitutive activation of the PDPK1/RSK2 signaling axis in multiple myeloma.
    Br J Haematol 2017; 178(4): 534-546.
  6. Iida S, Susuki K, Kusumoto S, Ri M, Tsukada N, Abe Y, Aoki M, Inagaki M.
    Safety and efficacy of daratumumab in Japanese patients with relapsed or refractory multiple myeloma: a multicenter, phase 1, dose-escalation study.
    Int J Hematol 2017; 106: 541-551.
  7. Akechi T, Aiki S, Sugano K, Uchida M, Yamada A, Komatsu H, Ishida T, Kusumoto S, Iida S, Okuyama T.
    Does cognitive decline decrease health utility value in older adult patients with cancer?
    Psychogeriatrics 2017; 17(3): 149-154.
  8. Narita T, Ishida T, Ito A, Masaki A, Kinoshita S, Suzuki S, Takino H, Yoshida T, Ri M, Kusumoto S, Komatsu H, Imada K, Tanaka Y, Takaori-Kondo A, Inagaki H, Scholz A, Lienau P, Kuroda T, Ueda R, Iida S.
    Cyclin-dependent kinase 9 is a novel specific molecular target in adult T-cell leukemia/lymphoma.
    Blood 2017;130(9): 1114-1124.
  9. Sakamoto Y, Masaki A, Aoyama S, Han S, Saida K, Fujii K, Takino H, Murase T, Iida S, Inagaki H.
    Improved clonality detection in B-cell lymphoma using a semi-nested modification of the BIOMED-2 PCR assay for IgH rearrangement: A paraffin-embedded tissue study.
    Pathol Int. 2017; 67(9): 453-460.
  10. Wong RWJ, Ngoc PCT, Leong WZ, Yam AWY, Zhang T, Asamitsu K, Iida S, Okamoto T, Ueda R, Gray NS, Ishida T, Sanda T.
    Enhancer profiling identifies critical cancer genes and characterizes cell identity in adult T-cell leukemia.
    Blood 2017;130(21): 2326-2338.
  11. Ri M, Matsue K, Sunami K, Shimazaki C, Hayashi A, Sunaga Y, Sasaki T, Suzuki K.
    Efficacy and safety of plerixafor for the mobilization/collection of peripheral hematopoietic stem cells for autologous transplantation in Japanese patients with multiple myeloma.
    Int J Hematol. 2017;106(4):562-572.